The changing face of phase 1 cancer clinical trials

Cancer

Volumn 115, Issue 8, 2009, Pages 1592-1597

  Craft, Barbara S ^a   Kurzrock, Razelle ^a   Lei, Xiudong ^a   Herbst, Roy ^b   Lippman, Scott ^b   Fu, Siqing ^a,b   Karp, Daniel D ^a,b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

Cancer drug development, research infrastructure; Phase 1 cancer clinical trials; Protocol requirement

Indexed keywords

CANCER RESEARCH; CLINICAL PROTOCOL; DRUG EFFICACY; DRUG RESEARCH; DRUG SAFETY; ELECTROCARDIOGRAPHY MONITORING; HUMAN; MAXIMUM TOLERATED DOSE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHYSICAL EXAMINATION; PRIORITY JOURNAL; REVIEW; VITAL SIGN;

BIOMEDICAL RESEARCH; CLINICAL PROTOCOLS; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; NEOPLASMS; PATIENT SELECTION; PHYSICAL EXAMINATION; RESEARCH DESIGN; UNITED STATES;

EID: 65249146114     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24171     Document Type: Review

References (27)

1. [No authors listed]. Critical role of phase I clinical trials in cancer treatment. J Clin Oncol. 1997;15:853-859.
2. Smith TL, Lee JJ, Kantarjian HM, et al. Design and results of phase I cancer clinical trials: three-year experience at M.D. Anderson Cancer Center. J Clin Oncol. 1996;14:287-295.
3. Gellar NL. Design of phase I and II clinical trials in cancer: a statistician's view. Cancer Invest. 1984;2:483-491.
4. Edler L. Statistical requirements of phase I studies. Onkologie. 1990;13:90-95.
5. Eisenhauer EA, O'Dwyer PJ, Christian M, Humphrey JS. Phase I clinical trial design in cancer drug development. J Clin Oncol. 2000;18:684-692.
6. Workman P, Aboagye EO, Chung Y, et al. Minimally invasive pharmacokinetic and pharmacodynamic technologies in hypothesis-testing clinical trials of innovative therapies. J Natl Cancer Inst. 2006;98:580-598.
7. Freireich EJ, Gehan EA, Rall DP, et al. Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother Rep. 1966;50:219-244.
8. Gelmon KA, Eisenhauer EA, Harris AL, et al. Anticancer agents targeting signaling molecules and cancer cell environment: challenges for drug development? J Natl Cancer Inst. 1999;91:1281-1287.
9. Parulekar WR, Eisenhauer EA. Novel endpoints and design of early clinical trials. Ann Oncol. 2002;13(suppl 4):139-143.
10. Parulekar SR, Eisenhauer EA. Phase I trial design for solid tumor studies of targeted, non-cytotoxic agents: theory and practice. JNatl Cancer Inst. 2004;96:990-997.
11. Korn EL. Nontoxicity endpoints in phase I trial designs for targeted, non-cytotoxic agents. J Natl Cancer Inst. 2004;96:977-978.
12. Shalala D. Protecting research subjects-what must be done. N Engl J Med. 2000;343:808-810.
13. Steinbrook R. Improving protection for research subjects. N Engl J Med. 2002;346:1425-1430.
14. Department of Health and Human Services. Protection of Human Subjects, 45 Code of Federal Regulations, Section 46 (June 18, 1991).
15. Horstmann E, McCabe MS, Grochow L, et al. Risks and benefits of phase 1 oncology trials, 1991 through 2002. Engl J Med. 2005;352:895-904.
16. Kurzrock R, Benjamin RS. Risks and benefits of phase 1 oncology trials, revisited. Engl J Med. 2005;352:930-932.
17. Roberts TG, Goulart BH, Squitieri L, et al. Trends in the risks and benefits to patients with cancer participating in phase 1 clinical trials. JAMA. 2004;292:2130-2140.
18. Sherman EJ, Rubin DM, Venkatraman E, et al. Using patients as their own controls for cost evaluation of phase I clinical trials. J Clin Oncol. 2004;22:1308-1314.
19. Ezekiel EJ, Schnipper LE, Kamin DY, et al. The costs of conducting clinical research. J Clin Oncol. 2003;21:1-6.
20. Goldman DP, Schoenbaum ML, Potosky AL, et al. Measuring the incremental cost of clinical cancer research. J Clin Oncol. 2001;19:105-110.
21. Goldman DP, Berry SH, McCabe MS, et al. Incremental treatment costs in National Cancer Institute-sponsored clinical trials. JAMA. 2003;289:2970-2977.
22. Bennett CL, Stinson TJ, Vogel V, et al. Evaluating the financial impact of clinical trials in oncology: results from a pilot study from the Association of American Cancer Institutes/Northwestern University Clinical Trials Costs and Charges Project. J Clin Oncol. 2000;18:2805-2810.
23. Quirk J, Schrag D, Radzyner M, et al. Clinical trial costs are similar to and may be less than standard care, and inpatient (INPT) charges at an academic medical center (AMC) are similar to major, minor, and non-teaching hospitals. Proc Am Soc Clin Oncol. 2000;19. Abstract 1696.
24. Wagner JL, Alberts SR, Sloan JA, et al. Incremental costs of enrolling cancer patients in clinical trials: a population-based study. J Natl Cancer Inst. 1999;19:847-853.
25. Brown ML. Cancer patient care in clinical trials sponsored by the National Cancer Institute: what does it cost? J Natl Cancer Inst. 1999;91:818-819.
26. Roche K, Paul N, Smuck B, et al. Factors affecting workload of cancer clinical trials: results of a multicenter study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2002;20:545-556.
27. Morganroth J. Cardiac repolarization and the safety of new drugs defined by electrocardiography. Clin Pharmacol Ther. 2007;81:108-113.